





Disclaimer



This presentation does not provide full disclosure of all material facts relating to Camposol Holding PLC and its direct or indirect subsidiaries, including but not limited to Camposol S.A., a sociedad anónima organized under the laws of Peru (together, the "Company" or "Camposol"), the securities of Camposol or a potential offering of such securities and is not subject to liability for misrepresentations under applicable securities legislation.

The contents hereof should not be construed as investment, legal, tax or other advice and you should consult your own advisers as to legal, business, tax and other related matters concerning an investment in Camposol

This presentation does not constitute a prospectus and should under no circumstances be understood as an offer to sell or the solicitation of an offer to buy securities nor will there be any sale of securities in any state, province or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Such an offer or solicitation can only be made by way of an effective registration statement or prospectus in accordance with the securities laws.

Certain statements herein are "forward-looking statements." Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continues," "expect," "estimate," "intend," "plans," "project," "target," and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "potential," "can," "may," or the negative of these terms or similar expressions are generally intended to identify forward-looking statements. These forward-looking statements speak only as of the date hereof and are based on Camposol's current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond Camposol's control. As a consequence, current plans, anticipated actions and future financial position and results of operations may differ significantly from those expressed in any forward-looking statements in the presentation. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented and we do not intend to update any of these forward-looking statements.

No representation or warranty is given in respect of the information contained herein, and neither the delivery of this presentation nor any investment in Camposol securities will under any circumstances create any implication that Camposol has updated the information contained herein. Information throughout the presentation provided by sources other than Camposol has not been independently verified. Differences between past performance and actual results may be material and adverse.

This presentation includes unaudited non-IFRS financial measures, including Adjusted EBITDA and Adjusted EBITDA Margin. We present non-IFRS measures when we believe that the additional information is useful and meaningful to investors. Non-IFRS financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similar measures presented by other companies. The presentation of non-IFRS financial measures is not intended to be a substitute for, and should not be considered in isolation from, the financial measures reported in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board.

Neither this presentation nor the information contained herein may be copied, reproduced, disclosed or distributed in whole or in part at any time without the prior written consent of Camposol. By accepting this presentation, the recipient acknowledges and agrees that this presentation and all of the information contained herein is confidential and subject to the confidentiality email previously acknowledged by the recipient. Without limiting the generality of the foregoing, the recipient will not reproduce this presentation in whole or in part and will hold all information contained in this presentation and the fact that Camposol is considering a potential initial public offering in confidence.

Speakers Today







Key Developments 1H 2023




- Total volume sold in 1H 2023 decreased by 5.6% compared to the same period last year, mainly driven by lower tangerines and mangoes volume.
- Total sales amounted to USD 154.1 million, up 1.0% compared to 1H 2022. While total sales only increased by 1%, the share of blueberry sales saw a 16.7% increase. Mango, grape and tangerine were the crops that experienced reduced sales.
- EBITDA from continuing operations amounted to USD 33.6 million in 1H 2023, up 44.4% compared to the same period 2022. EBITDA margin from continued operations increased to 21.8% from 15.2% in 1H 2022.
- LTM EBITDA as of June 30th, 2023, amounted to USD 72.5 million.
- We have followed the directive to carry out prioritized capital investments, including maintenance capex for crops and short-term growth capex, to alleviate cash pressure. This aligns with the strategic objective defined at the beginning of the year.





Operational overview 1H 2023






Highlights

- We had an improved first half.
- 5.6% reduction in volume sold in 1H 2023 driven by tangerines and mangoes.
- Revenue increased up to USD 154.1 million, driven by higher blueberry revenue.
- EBITDA for 1H 2023 was USD 33.6 million, which is 44.4% higher than 1H 2022.
- This improvement has been facilitated not only by enhanced crop performance, but also by the decreased freight expenses and a reduction in expenditures related to third-party services.


Operational overview 1H 2023







Highlights



The avocado campaign just begun, and we registered an increase in volume of 4.8% compared to 1H 2022 with a 5.5% increase in the average price.

Reduction in tangerine segment directly related to volume. This diminished volume has also been deferred to the upcoming months.

Liquidity & capital structure - cash flow



30.06.23	<u>31.12.22</u>	30.06.22
217,293	431,239	171,880
(182,260)	(416,903)	(170,386)
(15,404)	(24,232)	(11,275)
(6,749)	(6,743)	(2,597)
1,238	3,193	643
(151)	(706)	(588)
13,967	(14,152)	(12,323)
	217,293 (182,260) (15,404) (6,749) 1,238 (151)	217,293 431,239 (182,260) (416,903) (15,404) (24,232) (6,749) (6,743) 1,238 3,193 (151) (706)

Cash flow from investing activities			
Purchases of property, plant and equipment	(7,403)	(24,690)	(11,384)
Investment in biological assets	(19,786)	(47,756)	(18,097)
Purchases of intangibles, excluding goodwill	(363)	(2,499)	(709)
Dividends from associates	597	1,864	-
Loans granted to related parties	660	(1,000)	(934)
Proceeds from sale of property, plant and equipment	1	100	24
Net cash used in investing activities	(26,294)	(73,981)	(31,100)


Cash flow from financial activities			
Bank loans proceeds	295,701	439,100	132,000
Bank loans payments	(325,611)	(307,050)	(66,050)
Dividends distribution	-	(35,000)	(15,000)
Principal elements of lease liabilities payments	(4,600)	(11,657)	(4,908)
Long-term debt proceeds	47,710	-	-
Payments of long-term debt	(1)	(513)	(513)
Net cash provided by financial activities	13,199	84,880	45,529
Net (decrease) increase in cash during the period	872	(3,253)	2,106
Cash and cash equivalents at beginning of period	27,222	30,475	30,475
Cash and cash equivalents at end of period	28,094	27,222	32,581

- A comparison with 1H 2022 reveals an enhancement in our operating cash flow. This progress can be attributed to more efficient collections during the blueberry campaign in those months
- Our capital expenditure strategy remains focused on executing short-term maintenance and growth capex.
- We have disbursed nearly \$50 million in medium-term financing to replace short term debt.
- We've taken a short-term position due to the delayed start of the avocado campaign. as avocado and blueberry collections progress, we will work to reduce our debt levels in the second half of the year.


Liquidity & capital structure - leverage & debt profile




Net Debt / EBITDA



Debt profile





Comments

- During the first quarter of 2023, we were able to restructure USD 80 million in debt towards the medium-term, out of which nearly USD 50 million were already disbursed, the remaining was disbursed during August. This helped alleviate the short-term pressure on our cashflow.
- Additionally, we still have credit lines available for up to USD 115 million. This credit line serves as a buffer and ensures that we have the necessary resources to manage any potential short-term cash flow fluctuations.
- Net debt to EBITDA ratio still higher but lower than previous quarter.

Source: 1.

Includes short & long term debt without capitalized fees and interest



Summary

- We will continue monitoring market-available volumes and their consequent impact on price dynamics.
- We will persist in seeking comprehensive operational efficiencies across the organization to further enhance the company's performance.
- We will maintain our focus on liquidity and financial flexibility, aligning with our strategic approach of executing only short-term maintenance and growth capex, while concurrently reducing the company's debt levels in the upcoming months



Increase yield per hectare

Keep developing new agronomic technics.

New varieties.



Focus on controlling and reducing logistic costs

Ocean freight.



Strengthen commercial leverage

Expand penetration in retail channel.

Continue developing the Asian market



Closely monitor longterm investments in Colombia, Uruguay, Chile and Mexico.



Prioritize liquidity

Only maintenance and short-term growth capex.

Maximize liquidity sources.

Reduce debt level.

No dividend distribution.



Financial statements - Income statement



14

	For the period ended	
	30.06.2023*	30.06.22*
Revenue	154,054	152,624
Cost of sales	(108,577)	(114,484)
Cost of sales	(93,258)	(99,816)
Depreciation of bearer plants	(15,319)	(14,668)
Gross profit before adjustment for biological assets	45,477	38,140
Net adjustment from change in f.a. of bio. assets	(4,274)	(28,085)
Profit after adjustment from biological assets	41,203	10,055
Selling expenses	(27,152)	(28,393)
Administrative expenses	(10,438)	(11,290)
Other expenses	(3,270)	(2,596)
Otherincome	417	332
Net foreign exchange transactions gains (losses)	(2,496)	(3,580)
Operating profit	(1,736)	(35,472)
Share of gain (loss) of associated companies	167	770
Finance income	231	41
Finance costs	(22,300)	(14,306)
Profit (loss) before income tax	(23,638)	(48,967)
Income tax	(1,348)	(26)
Deferred income tax	3,033	3,207
Profit (loss) for the period	(21,953)	(45,786)
BITDA before fair value adjustment	33,567	23,250

** Audited

Financial statements - Balance sheet



	For the period 30.06.2023*	For the period 31.03.2023*
Assets		
Non-current assets		
Property, plant and equipment, net	737,782	731,283
Right of use asset	40,773	42,375
Investments in associated companies	5,271	5,701
Intangibles	12,885	13,162
Deferred income tax	14,628	12,800
Other accounts receivable	408	408
	811,747	805,729
Current assets		
Assets held for sale	-	-
Prepaid expenses	2,101	1,899
Current portion of biological assets	172,404	162,684
Inventories	52,966	33,878
Other accounts receivable	23,786	21,939
Trade accounts receivable	12,054	38,628
Cash subject to restriction	-	-
Cash and cash equivalents	28,094	39,195
	291,405	298,223
Total assets	1,103,152	1,103,952

	For the period 30.06.2023*	For the period 31.03.2023*
Equity and liabilities		
Capital and reserve attributable to		
shareholders of the Company		
Share capital	10,000	10,000
Share premium	-	-
Revaluation of assets	170,092	170,092
Retained earnings	80,994	94,566
Former parent net investment	_	-
	261,086	274,658
Minority interests	- 989	- 989
Total equity	260,097	273,669
Non-current liabilities		
Long-term debt	356,735	356,913
Lease liability	57,924	37,902
Deferred income tax	123,189	122,539
Other payables		-
	537,848	517,354
Current liabilities		
Accounts payable to related companies	32	31
Current portion of long-term debt	7,815	2,044
Current portion of lease liability	15,739	10,014
Current tax liabilities	-	4,647
Trade payables	77,723	84,442
Other payables	20,577	23,563
Bank loans	183,321	188,188
	305,207	312,929
Total liabilities	843,055	830,283
Total equity and liabilities	1,103,152	1,103,952

^{*} Non audited







Búscanos como CamposolCares en:







Búscanos como Camposol en:



Para mas información por favor conectarse a : www.camposol.com.pe

For more information please log into: www.camposol.com.pe